G.A.P. Pharmaceuticals S.A.
About GAP
Product rangesPharmaceutical ProductsCosmetics and OTC Veterinary Products Soft Gels New Products
Home page > Product Ranges > Pharmaceutical Products >


PackagingBox containing 30 tablets (5 blisters x 6 tablets).

LISOLIP (gemfibrozil tablets) is a lipid regulating agent which decreases serum triglycerides and very low density lipoprotein (VLDL) cholesterol, and increases high density lipoprotein (HDL) cholesterol. While modest decreases in total and low density lipoprotein (LDL) cholestrol may be observed with LISOLIP therapy, treatment of patients with elevated triglycerides due to Type IV hyperlipoproteinemia often results in a rise in LDL-cholesterol. LDL-cholesterol in Type IIb patients with elevations of both serum LDL-cholestrol and triglycerides are, in general, minimally affected by gemfibrozil treatment; however, gemfibrozil usually raises levels of HDL subfractions HDL 2 and HDL 3 , as well as apolipoproteins Al and All.
Epidemiological studies have shown that both low HDL-cholesterol and high LDL-cholesterol are independent risk factors for coronary heart disease.

Aghisilaou 46, 173 41 Aθήνα,
Tel: 210-9310980-4, Fax: 210-9338759 email : gap@gap.gr